Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study
We investigated the design and analysis of observational booster vaccine effectiveness (VE)
studies by performing a scoping review of booster VE literature with a focus on study design …
studies by performing a scoping review of booster VE literature with a focus on study design …
[HTML][HTML] Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections
Understanding mucosal antibody responses from SARS-CoV-2 infection and/or vaccination
is crucial to develop strategies for longer term immunity, especially against emerging viral …
is crucial to develop strategies for longer term immunity, especially against emerging viral …
[HTML][HTML] COVID-19 Vaccine Effectiveness of Booster Doses Against Delta and Omicron Variants Over Follow-up Times Using Longitudinal Meta-analysis
F Mostafavi, M Bahardoust, F Sera… - Journal of Research …, 2024 - pmc.ncbi.nlm.nih.gov
Background: COVID-19 is a viral disease caused by the SARS-CoV-2, leading to several
variants. This study aimed to examine the effectiveness of booster doses against the Delta …
variants. This study aimed to examine the effectiveness of booster doses against the Delta …
Detection and isolation of infectious SARS-CoV-2 omicron subvariants collected from residential settings
WB Vass, S Nannu Shankar, JA Lednicky… - Aerosol Science and …, 2023 - Taylor & Francis
Airborne transmission of infectious (viable) SARS-CoV-2 is increasingly accepted as the
primary manner by which the virus is spread from person to person. Risk of exposure to …
primary manner by which the virus is spread from person to person. Risk of exposure to …
A Reanalysis of the FDA's Benefit-Risk Assessment of Moderna's mRNA-1273 COVID Vaccine: For 18-25-Year-Old Males, Risks Exceeded Benefits Relative to …
PS Bourdon, R Duriseti, HC Gromoll, DK Dalton… - arXiv preprint arXiv …, 2024 - arxiv.org
The FDA conducted a benefit-risk assessment for Moderna's COVID vaccine mRNA-1273
prior to its full approval (announced 1/31/2022). The FDA focused its assessment on males …
prior to its full approval (announced 1/31/2022). The FDA focused its assessment on males …
Vaccination and its impact on healthcare utilization in two groups of vaccinated and unvaccinated patients with COVID‐19: A cross‐sectional study in Iran between …
E Kharazmi, M Bayati… - Health Science …, 2024 - Wiley Online Library
Abstract Background and Aims One of the main responsibilities of health systems impacted
by the global Coronavirus disease 2019 (COVID‐19) pandemic, where the first case was …
by the global Coronavirus disease 2019 (COVID‐19) pandemic, where the first case was …
Lasting first impression: Pre-existing immunity restricts mucosal antibody responses during Omicron breakthrough
Understanding mucosal antibody responses from SARS-CoV-2 infection and/or vaccination
is crucial to develop strategies for longer term immunity, especially against emerging viral …
is crucial to develop strategies for longer term immunity, especially against emerging viral …